|
Aug 6
|
Teva’s Ajovy becomes first migraine prevention drug approved for children
|
|
Aug 6
|
FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine
|
|
Aug 5
|
Endocarditis Market Global and Regional Research Report 2025-2035 | AI and Molecular Diagnostics Set to Revolutionize Endocarditis Management
|
|
Jul 31
|
TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales
|
|
Jul 31
|
Multiple Sclerosis Clinical Trials Market Landscape Report 2025 Featuring Biogen, Novartis, Sanofi, Merck, Teva, Bayer, Roche, Bristol-Myers Squibb, Laboratory Corp of America, IQVIA
|
|
Jul 30
|
Why Drugmaker Teva Pharmaceutical Narrowed Full-Year Guidance After Beating Q2 Earnings
|
|
Jul 30
|
Teva CEO on Tariffs, Generic Drugs Market, MFN Pricing
|
|
Jul 30
|
Teva Pharma Boosts Outlook For Key Innovative Drugs Austedo, Ajovy, Uzedy
|
|
Jul 30
|
Alvotech Gears Up to Report Q2 Earnings: Here's What to Expect
|
|
Jul 30
|
Compared to Estimates, Teva Pharmaceutical Industries (TEVA) Q2 Earnings: A Look at Key Metrics
|
|
Jul 30
|
UZEDY® Accelerates: 2025 Revenue Outlook Raised to $190–$200M (from ~$160M); Olanzapine LAI on Track for Submission in 2025
|
|
Jul 30
|
Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components
|
|
Jul 29
|
Countdown to Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Wall Street Forecasts for Key Metrics
|
|
Jul 28
|
This is the Most Dangerous Week for Investors in 20 Years
|
|
Jul 24
|
Deckers Brands Reports First Quarter Fiscal Year 2026 Financial Results
|
|
Jul 21
|
EdgeOne Medical Announces Appointment of Michael Denzer as VP, Client Relations to Further Elevate Product Innovation and Client Partnerships
|
|
Jul 21
|
Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?
|
|
Jul 18
|
Trump Aims Tariff Double Whammy at Industries, Nations by Aug. 1
|
|
Jul 11
|
TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?
|
|
Jul 11
|
Untapped Patient Base, Ingrezza Growth Keep Neurocrine (NBIX) on Guggenheim’s Buy List
|